Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MNPR-101-PCTA-177Lu
- Development stage
- Phase 1
- Lead developer
- Monopar Therapeutics
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MNPR-101-PCTA-177Lu is a therapeutic radiopharmaceutical consisting of the humanized monoclonal antibody MNPR-101, which targets the urokinase plasminogen activator receptor (uPAR), conjugated to the beta-emitting radioisotope lutetium-177 via a PCTA chelator. Developed by Monopar Therapeutics, the drug is designed to deliver targeted radiation to uPAR-expressing solid tumors, including aggressive cancers such as pancreatic, ovarian, triple-negative breast, and colorectal cancers. uPAR is a cell-surface protein highly expressed in many cancers and is associated with tumor growth, invasion, and metastasis. The drug is currently being evaluated in Phase 1 clinical trials and an expanded access program, often following patient selection using the companion imaging agent MNPR-101-DFO*-89Zr.
- Brand names
- MNPR-101-LuMNPR101-LuMNPR 101-Lu
- Other names
- MNPR-101-PCTA-Lutetium-177MNPR101-PCTA-Lutetium-177MNPR 101-PCTA-Lutetium-177
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on MNPR-101-PCTA-177Lu.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MNPR-101-PCTA-177Lu.